Clinical trial
Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in…
NCT00338442 · Cangene Corporation, Industry · Approved for marketing
Key facts
| NCT number | NCT00338442 |
|---|---|
| Title | Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection |
| Official title | Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection |
| Lead sponsor | Cangene Corporation, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Varicella |
| Intervention type | Drug |
| Interventions | VariZIG™ |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 20, 2006 |
| Last update posted | Apr 4, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: